Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710501 | 0.95 | RAB9A (0.42) | RAB9ASMN1; SMN2NPC1LMNANFKB1 | |
| SCHEMBL4881605 | 0.85 | KMT2A (0.43) | RAB9ASMN1; SMN2NPC1ALDH1A1KMT2A | |
| SCHEMBL4880879 | 0.84 | RAB9A (0.37) | RAB9ASMN1; SMN2NPC1LMNANFKB1 | |
| SCHEMBL14066580 | 0.83 | MAPT (0.53) | SMN1; SMN2ALDH1A1NPSR1KMT2AL3MBTL1 | |
| SCHEMBL4881051 | 0.82 | RAB9A (0.38) | RAB9ASMN1; SMN2NPC1LMNANFKB1 | |
| SCHEMBL14066562 | 0.82 | RAB9A (0.49) | RAB9ASMN1; SMN2NPC1LMNANFKB1 | |
| SCHEMBL4873941 | 0.82 | GRM5 (0.40) | RAB9ASMN1; SMN2NPC1LMNANFKB1 | |
| SCHEMBL14066579 | 0.82 | GRM5 (0.40) | RAB9ASMN1; SMN2NPC1LMNANFKB1 | |
| SCHEMBL4886038 | 0.81 | KMT2A (0.40) | RAB9ASMN1; SMN2NPC1ALDH1A1KMT2A | |
| SCHEMBL4709552 | 0.81 | RAB9A (0.50) | RAB9ASMN1; SMN2NPC1LMNANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | F2, UQCRB, F12 | RAB9A 2655/4885SMN1; SMN2 2534/4885NPC1 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.